@article{7e2d1e4ebd8145ae8001072cadb7765f,
title = "A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial",
abstract = "Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI-1 trial, we evaluated lenalidomide (LEN) in combination with low-dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone. Two hundred and two patients, randomised 1:1, were evaluable. Overall response rate (CR + CRi) was higher for LDAC + LEN versus LDAC (26% and 13.7% respectively p = 0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC + LEN and LDAC respectively). The addition of LEN was associated with increased toxicity and supportive care requirements.",
keywords = "Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cytarabine, Humans, Lenalidomide/therapeutic use, Leukemia, Myeloid, Acute/drug therapy, Remission Induction, clinical trial, low-dose cytosine arabinoside, acute myeloid leukaemia, elderly, lenalidomide",
author = "Mhairi Copland and Cono Ariti and Thomas, {Ian F} and Laura Upton and Mia Sydenham and Priyanka Mehta and Shahid Islam and Lars Kjeldsen and Burnett, {Alan K} and Hills, {Robert K} and Nigel Russell and Mike Dennis and {UK NCRI AML Study Group}",
note = "{\textcopyright} 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",
year = "2024",
month = mar,
doi = "10.1111/bjh.19220",
language = "English",
volume = "204",
pages = "871--876",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "3",
}